Dr Van Gorp on the Role of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

“[Findings reaffirm] again that the use of mirvetuximab soravtansine [in patients with folate receptor α–positive, platinum-resistant ovarian cancer], even after a very long follow-up time, with this efficacy and safety profile, is definitely the best treatment to give these patients.”

Toon Van Gorp, MD, PhD, a full professor and gynecologic oncologist at the Universitair Ziekenhuis Leuven in Belgium, discussed the role mirvetuximab soravtansine-gynx (Elahere) has played for the treatment of in patients with folate receptor α (FRα)–positive, platinum-resistant ovarian cancer, and highlighted persisting unmet needs in this space.

A final overall survival (OS) analysis from the phase 3 MIRASOL trial (NCT04209855) determined that treatment with mirvetuximab soravtansine maintained significant activity over investigator’s choice of chemotherapy in patients with FRα-positive, platinum-resistant ovarian cancer. Of note, at a median follow-up of 30.5 months, patients on the study treated with mirvetuximab soravtansine (n = 227) achieved a median OS of 16.85 months (95% CI, 14.36-19.78) vs 13.34 months (95% CI, 11.37-15.15) in patients treated with investigator’s choice chemotherapy (n = 226; HR, 0.68; 95% CI, 0.54-0.84; P = .0004).

These positive findings can give hope to this patient population, who historically have had a poorer prognosis of 12 to 13 months, Van Gorp began. He emphasized that findings from the final OS analysis of MIRASOL reaffirmed that the use of mirvetuximab soravtansine is the most optimal treatment option for this patient population, even after a long follow-up time.

Van Gorp noted that although these are positive changes in this space, further research must continue with mirvetuximab soravtansine. Moving forward, he said it should be studied in earlier lines of therapy, frontline therapy, and in patients with platinum-sensitive disease. Currently, only approximately 35% of the patient population is eligible to be treated with mirvetuximab soravtansine, he added. Van Gorp concluded that there are ongoing studies assessing these unmet needs, and he hopes that studies can also evaluate patients with lower expressions.